Loading…
Reported covered position: Senior Health Counsel, Health Counsel - House Energy and Commerce Committee (Rep. Frank Pallone); Counsel, Legislative Assistant - Rep. Kurt Schrader
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: BAYLOR COLLEGE OF MEDICINE · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
NIH Federal grant issues FY27 Appropriations Proposed OMB Grant Rule Facilities and Administration issues Issues related to Dept. of Education negotiated rulemaking on P.L. 119-21 (H.R. 1) Commerce, Justice, Science (H.R. 5342; S. 2354) Labor-HHS (H.R. 5304; S. 2587)
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: BAYLOR COLLEGE OF MEDICINE · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
BECTON, DICKINSON AND COMPANY via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · Q3
Issues related to medical device reimbursement.
Issues related medical technology regulation.
Filing targets: State, Dept of (DOS)
TOLMAR, INC. via
Source: Senate LDA
| LILLY USA, LLC |
| 4 |
| 2025–2026 |
| PIERRE FABRE PHARMACEUTICALS, INC. | 4 | 2025–2026 |
| ASANA VOICES, FORMERLY REPORTED AS, ASANA VOICES, LLC | 3 | 2026 |
| ELANCO ANIMAL HEALTH | 3 | 2026 |
| BECTON, DICKINSON AND COMPANY | 2 | 2026 |
| CAREQUEST INSTITUTE FOR ORAL HEALTH, INC. | 2 | 2026 |
| GRINDR LLC | 2 | 2026 |
| TOLMAR, INC. | 2 | 2026 |
| FERRING PHARMACEUTICALS, INC. | 1 | 2026 |
NIH Federal grant issues FY27 Appropriations Proposed OMB Grant Rule Facilities and Administration issues Garner support for Building a Constellation of Outer Space Partners at the United Nations Funding Opportunity Issues related to Dept. of Education negotiated rulemaking on P.L. 119-21 (H.R. 1) Commerce, Justice, Science (H.R. 5342; S. 2354) Labor-HHS (H.R. 5304; S. 2587)
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: BAYLOR COLLEGE OF MEDICINE · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
NIH Federal grant issues FY27 Appropriations Facilities and Administration issues Issues related to Dept. of Education negotiated rulemaking on P.L. 119-21 (H.R. 1) Commerce, Justice, Science (H.R. 5342; S. 2354) Labor-HHS (H.R. 5304; S. 2587)
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: CAREQUEST INSTITUTE FOR ORAL HEALTH, INC. · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Oral health issues and screenings for oral cancer. Access to oral healthcare and issues related to Medicare Dental. P.L. 119-21 (H.R. 1): One Big Beautiful Bill implementation Fluoride Human Health Toxicity Assessment
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to cell and gene therapy and radioligand therapies Pharmaceutical pricing Issues related to the development of therapies for rare diseases 340B Drug Discount Program Supply chain issues affecting pharmaceutical products Implementation of the Inflation reduction Act Pharmaceutical innovation PBM policy issues HR 1672 The Maintaining Investments in New Innovations (MINI) Act Intellectual property Issues Tariff issues affecting the pharmaceutical industry EPIC Act Most Favored Nation (MFN) policy Tribal health issues
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to cell and gene therapy and radioligand therapies Pharmaceutical pricing Issues related to the development of therapies for rare diseases 340B Drug Discount Program Supply chain issues affecting pharmaceutical products Implementation of the Inflation reduction Act Pharmaceutical innovation PBM policy issues HR 1672 The Maintaining Investments in New Innovations (MINI) Act Intellectual property Issues Tariff issues affecting the pharmaceutical industry EPIC Act Most Favored Nation (MFN) policy
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to cell and gene therapy and radioligand therapies Pharmaceutical pricing Issues related to the development of therapies for rare diseases 340B Drug Discount Program Supply chain issues affecting pharmaceutical products Implementation of the Inflation reduction Act Pharmaceutical innovation PBM policy issues HR 1672 The Maintaining Investments in New Innovations (MINI) Act Intellectual property Issues Tariff issues affecting the pharmaceutical industry EPIC Act Most Favored Nation (MFN) policy
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
Client: NOVAVAX, INC. · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to federal vaccine programs and vaccine regulatory frameworks. FDA funding and advocacy H.R.4121 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
Client: NOVAVAX, INC. · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to federal vaccine programs and vaccine regulatory frameworks. FDA funding and advocacy H.R.4121 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
Client: NOVAVAX, INC. · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to federal vaccine programs and vaccine regulatory frameworks. FDA funding and advocacy H.R.4121 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: BAYLOR COLLEGE OF MEDICINE · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
NIH Federal grant issues FY27 Appropriations Proposed OMB Grant Rule Facilities and Administration issues Garner support for Building a Constellation of Outer Space Partners at the United Nations Funding Opportunity Issues related to Dept. of Education negotiated rulemaking on P.L. 119-21 (H.R. 1) Commerce, Justice, Science (H.R. 5342; S. 2354) Labor-HHS (H.R. 5304; S. 2587)
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: BAYLOR COLLEGE OF MEDICINE · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
NIH Federal grant issues FY27 Appropriations Facilities and Administration issues Issues related to Dept. of Education negotiated rulemaking on P.L. 119-21 (H.R. 1) Commerce, Justice, Science (H.R. 5342; S. 2354) Labor-HHS (H.R. 5304; S. 2587)
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: BAYLOR COLLEGE OF MEDICINE · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
NIH Federal grant issues FY27 Appropriations Proposed OMB Grant Rule Facilities and Administration issues Issues related to Dept. of Education negotiated rulemaking on P.L. 119-21 (H.R. 1) Commerce, Justice, Science (H.R. 5342; S. 2354) Labor-HHS (H.R. 5304; S. 2587)
Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026
Client: BAYLOR COLLEGE OF MEDICINE · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
NIH Federal grant issues FY27 Appropriations Facilities and Administration issues Issues related to Dept. of Education negotiated rulemaking on P.L. 119-21 (H.R. 1) Commerce, Justice, Science (H.R. 5342; S. 2354) Labor-HHS (H.R. 5304; S. 2587)
Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026
Client: BAYLOR COLLEGE OF MEDICINE · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
NIH Federal grant issues FY27 Appropriations Proposed OMB Grant Rule Facilities and Administration issues Issues related to Dept. of Education negotiated rulemaking on P.L. 119-21 (H.R. 1) Commerce, Justice, Science (H.R. 5342; S. 2354) Labor-HHS (H.R. 5304; S. 2587)
Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026
Client: BAYLOR COLLEGE OF MEDICINE · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
NIH Federal grant issues FY27 Appropriations Proposed OMB Grant Rule Facilities and Administration issues Garner support for Building a Constellation of Outer Space Partners at the United Nations Funding Opportunity Issues related to Dept. of Education negotiated rulemaking on P.L. 119-21 (H.R. 1) Commerce, Justice, Science (H.R. 5342; S. 2354) Labor-HHS (H.R. 5304; S. 2587)
Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026
Client: BAYLOR COLLEGE OF MEDICINE · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
NIH Federal grant issues FY27 Appropriations Facilities and Administration issues Issues related to Dept. of Education negotiated rulemaking on P.L. 119-21 (H.R. 1) Commerce, Justice, Science (H.R. 5342; S. 2354) Labor-HHS (H.R. 5304; S. 2587)
Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026
Client: BAYLOR COLLEGE OF MEDICINE · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
NIH Federal grant issues FY27 Appropriations Proposed OMB Grant Rule Facilities and Administration issues Garner support for Building a Constellation of Outer Space Partners at the United Nations Funding Opportunity Issues related to Dept. of Education negotiated rulemaking on P.L. 119-21 (H.R. 1) Commerce, Justice, Science (H.R. 5342; S. 2354) Labor-HHS (H.R. 5304; S. 2587)
Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026
Client: BAYLOR COLLEGE OF MEDICINE · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
NIH Federal grant issues FY27 Appropriations Proposed OMB Grant Rule Facilities and Administration issues Issues related to Dept. of Education negotiated rulemaking on P.L. 119-21 (H.R. 1) Commerce, Justice, Science (H.R. 5342; S. 2354) Labor-HHS (H.R. 5304; S. 2587)
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: BAYLOR COLLEGE OF MEDICINE · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
NIH Federal grant issues FY27 Appropriations Facilities and Administration issues Issues related to Dept. of Education negotiated rulemaking on P.L. 119-21 (H.R. 1) Commerce, Justice, Science (H.R. 5342; S. 2354) Labor-HHS (H.R. 5304; S. 2587)
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: BAYLOR COLLEGE OF MEDICINE · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
NIH Federal grant issues FY27 Appropriations Proposed OMB Grant Rule Facilities and Administration issues Issues related to Dept. of Education negotiated rulemaking on P.L. 119-21 (H.R. 1) Commerce, Justice, Science (H.R. 5342; S. 2354) Labor-HHS (H.R. 5304; S. 2587)
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: BAYLOR COLLEGE OF MEDICINE · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
NIH Federal grant issues FY27 Appropriations Proposed OMB Grant Rule Facilities and Administration issues Garner support for Building a Constellation of Outer Space Partners at the United Nations Funding Opportunity Issues related to Dept. of Education negotiated rulemaking on P.L. 119-21 (H.R. 1) Commerce, Justice, Science (H.R. 5342; S. 2354) Labor-HHS (H.R. 5304; S. 2587)
Advancing legislation on cardiovascular health and related issues. S.5469 HEART Foundation Act
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: BAYLOR COLLEGE OF MEDICINE · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
NIH Federal grant issues H.R.1 One Big Beautiful Bill implementation FY26 Appropriations Facilities and Administration issues Issues related to Dept. of Education negotiated rulemaking on P.L. 119-21 (H.R. 1) Agriculture (H.R. 4121; S. 2256) Commerce, Justice, Science (H.R. 5342; S. 2354) Homeland Security (H.R. 4213) Labor-HHS (H.R. 5304; S. 2587) Military Construction and Veterans Affairs (H.R. 3944) State & Foreign Operations (H.R. 4779)
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to cell and gene therapy and radioligand therapies Pharmaceutical pricing Issues related to the development of therapies for rare diseases 340B Drug Discount Program Supply chain issues affecting pharmaceutical products Implementation of the Inflation reduction Act Pharmaceutical innovation PBM policy issues HR 1672 The Maintaining Investments in New Innovations (MINI) Act Intellectual property Issues Tariff issues affecting the pharmaceutical industry EPIC Act Most Favored Nation (MFN) policy
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to cell and gene therapy and radioligand therapies Pharmaceutical pricing Issues related to the development of therapies for rare diseases 340B Drug Discount Program Supply chain issues affecting pharmaceutical products Implementation of the Inflation reduction Act Pharmaceutical innovation PBM policy issues HR 1672 The Maintaining Investments in New Innovations (MINI) Act Intellectual property Issues Tariff issues affecting the pharmaceutical industry EPIC Act Most Favored Nation (MFN) policy
Military Construction and Veterans Affairs, Agriculture, and Legislative Branch Appropriations Act, 2026
Client: BAYLOR COLLEGE OF MEDICINE · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
NIH Federal grant issues H.R.1 One Big Beautiful Bill implementation FY26 Appropriations Facilities and Administration issues Issues related to Dept. of Education negotiated rulemaking on P.L. 119-21 (H.R. 1) Agriculture (H.R. 4121; S. 2256) Commerce, Justice, Science (H.R. 5342; S. 2354) Homeland Security (H.R. 4213) Labor-HHS (H.R. 5304; S. 2587) Military Construction and Veterans Affairs (H.R. 3944) State & Foreign Operations (H.R. 4779)
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
Client: BAYLOR COLLEGE OF MEDICINE · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
NIH Federal grant issues H.R.1 One Big Beautiful Bill implementation FY26 Appropriations Facilities and Administration issues Issues related to Dept. of Education negotiated rulemaking on P.L. 119-21 (H.R. 1) Agriculture (H.R. 4121; S. 2256) Commerce, Justice, Science (H.R. 5342; S. 2354) Homeland Security (H.R. 4213) Labor-HHS (H.R. 5304; S. 2587) Military Construction and Veterans Affairs (H.R. 3944) State & Foreign Operations (H.R. 4779)
Department of Homeland Security Appropriations Act, 2026
Client: BAYLOR COLLEGE OF MEDICINE · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
NIH Federal grant issues H.R.1 One Big Beautiful Bill implementation FY26 Appropriations Facilities and Administration issues Issues related to Dept. of Education negotiated rulemaking on P.L. 119-21 (H.R. 1) Agriculture (H.R. 4121; S. 2256) Commerce, Justice, Science (H.R. 5342; S. 2354) Homeland Security (H.R. 4213) Labor-HHS (H.R. 5304; S. 2587) Military Construction and Veterans Affairs (H.R. 3944) State & Foreign Operations (H.R. 4779)
National Security, Department of State, and Related Programs Appropriations Act, 2026
Client: BAYLOR COLLEGE OF MEDICINE · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
NIH Federal grant issues H.R.1 One Big Beautiful Bill implementation FY26 Appropriations Facilities and Administration issues Issues related to Dept. of Education negotiated rulemaking on P.L. 119-21 (H.R. 1) Agriculture (H.R. 4121; S. 2256) Commerce, Justice, Science (H.R. 5342; S. 2354) Homeland Security (H.R. 4213) Labor-HHS (H.R. 5304; S. 2587) Military Construction and Veterans Affairs (H.R. 3944) State & Foreign Operations (H.R. 4779)
Preserving Patient Access to Long-Term Care Pharmacies Act
Client: CARDINAL HEALTH, INC. · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
General issues affecting the health care industry such as drug pricing, pharmaceutical drugs, medical devices, workforce shortages, and product shortages. The Preserving Patient Access to Long-Term Care Pharmacies Act (H.R. 5031 / S. 3159)
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: BAYLOR COLLEGE OF MEDICINE · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
NIH Federal grant issues H.R.1 One Big Beautiful Bill implementation FY26 Appropriations Facilities and Administration issues Issues related to Dept. of Education negotiated rulemaking on P.L. 119-21 (H.R. 1) Agriculture (H.R. 4121; S. 2256) Commerce, Justice, Science (H.R. 5342; S. 2354) Homeland Security (H.R. 4213) Labor-HHS (H.R. 5304; S. 2587) Military Construction and Veterans Affairs (H.R. 3944) State & Foreign Operations (H.R. 4779)
Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026
Client: BAYLOR COLLEGE OF MEDICINE · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
NIH Federal grant issues H.R.1 One Big Beautiful Bill implementation FY26 Appropriations Facilities and Administration issues Issues related to Dept. of Education negotiated rulemaking on P.L. 119-21 (H.R. 1) Agriculture (H.R. 4121; S. 2256) Commerce, Justice, Science (H.R. 5342; S. 2354) Homeland Security (H.R. 4213) Labor-HHS (H.R. 5304; S. 2587) Military Construction and Veterans Affairs (H.R. 3944) State & Foreign Operations (H.R. 4779)
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
Client: BAYLOR COLLEGE OF MEDICINE · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
NIH Federal grant issues H.R.1 One Big Beautiful Bill implementation FY26 Appropriations Facilities and Administration issues Issues related to Dept. of Education negotiated rulemaking on P.L. 119-21 (H.R. 1) Agriculture (H.R. 4121; S. 2256) Commerce, Justice, Science (H.R. 5342; S. 2354) Homeland Security (H.R. 4213) Labor-HHS (H.R. 5304; S. 2587) Military Construction and Veterans Affairs (H.R. 3944) State & Foreign Operations (H.R. 4779)
Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026
Client: BAYLOR COLLEGE OF MEDICINE · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
NIH Federal grant issues H.R.1 One Big Beautiful Bill implementation FY26 Appropriations Facilities and Administration issues Issues related to Dept. of Education negotiated rulemaking on P.L. 119-21 (H.R. 1) Agriculture (H.R. 4121; S. 2256) Commerce, Justice, Science (H.R. 5342; S. 2354) Homeland Security (H.R. 4213) Labor-HHS (H.R. 5304; S. 2587) Military Construction and Veterans Affairs (H.R. 3944) State & Foreign Operations (H.R. 4779)
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: BAYLOR COLLEGE OF MEDICINE · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
NIH Federal grant issues H.R.1 One Big Beautiful Bill implementation FY26 Appropriations Facilities and Administration issues Issues related to Dept. of Education negotiated rulemaking on P.L. 119-21 (H.R. 1) Agriculture (H.R. 4121; S. 2256) Commerce, Justice, Science (H.R. 5342; S. 2354) Homeland Security (H.R. 4213) Labor-HHS (H.R. 5304; S. 2587) Military Construction and Veterans Affairs (H.R. 3944) State & Foreign Operations (H.R. 4779)
Preserving Patient Access to Long-Term Care Pharmacies Act
Client: CARDINAL HEALTH, INC. · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
General issues affecting the health care industry such as drug pricing, pharmaceutical drugs, medical devices, workforce shortages, and product shortages. The Preserving Patient Access to Long-Term Care Pharmacies Act (H.R. 5031 / S. 3159)
2026 · third_quarter · Q3
Advocacy around issues affecting the pharmaceutical industry, such as the Medicare Drug Price Negotiation Program under the Inflation Reduction Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVARTIS via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · Q3
Issues related to cell and gene therapy and radioligand therapies Pharmaceutical pricing Issues related to the development of therapies for rare diseases 340B Drug Discount Program Supply chain issues affecting pharmaceutical products Implementation of the Inflation reduction Act Pharmaceutical innovation PBM policy issues HR 1672 The Maintaining Investments in New Innovations (MINI) Act Intellectual property Issues Tariff issues affecting the pharmaceutical industry EPIC Act Most Favored Nation (MFN) policy Tribal health issues
Filing targets: Indian Health Service, SENATE
ELANCO ANIMAL HEALTH via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · Q3
Advocacy surrounding the development of pharmaceuticals for animals
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, U.S. Trade Representative (USTR)
KYVERNA THERAPEUTICS, INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · Q3
Outreach regarding cell therapies for autoimmune diseases.
Filing targets: Health & Human Services, Dept of (HHS)
NOVAVAX, INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · Q3
Issues related to federal vaccine programs and vaccine regulatory frameworks. FDA funding and advocacy H.R.4121 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GRINDR LLC via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · Q3
HIV prevention, PEPFAR, family formation
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), Treasury, Dept of
FERRING PHARMACEUTICALS INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · Q3
Issues related to microbiome, oncology, & fertility Issues related to formulary tier status Drug pricing policy Healthcare policy in the NDAA IVF Tax credit FDA Review programs
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE
ELI LILLY AND COMPANY via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · Q3
Issues related to the pharmaceutical industry Treat and Reduce Obesity Act Pharmaceutical tariffs Safe Drugs Act
Issues related to biotechnology legislation Diagnostic tests Clinical trial issues Issues related to supply chain
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CARDINAL HEALTH, INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · Q3
General issues affecting the health care industry such as drug pricing, pharmaceutical drugs, medical devices, workforce shortages, and product shortages.
Pharmaceutical tariffs Supply chain issues affecting the pharmaceutical industry
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BAYLOR COLLEGE OF MEDICINE via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · Q3
NIH Federal grant issues FY27 Appropriations Proposed OMB Grant Rule Facilities and Administration issues Garner support for Building a Constellation of Outer Space Partners at the United Nations Funding Opportunity Issues related to Dept. of Education negotiated rulemaking on P.L. 119-21 (H.R. 1) Commerce, Justice, Science (H.R. 5342; S. 2354) Labor-HHS (H.R. 5304; S. 2587)
Filing targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
ASANA VOICES via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · Q3
Advancing legislation on cardiovascular health and related issues. S.5469 HEART Foundation Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CAREQUEST INSTITUTE FOR ORAL HEALTH, INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · Q3
Oral health issues and screenings for oral cancer. Access to oral healthcare and issues related to Medicare Dental. Issues related to Medicare and Medicaid dental Fluoride Human Health Toxicity Assessment Expanded eligibility for dental care for veterans and veterans in rural areas
Filing targets: Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
BECTON, DICKINSON AND COMPANY via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · RR
Issues related to medical technology regulation. Issues related to medical device reimbursement. Medical device supply chain and international trade issues.
Issues related to medical technology regulation. Issues related to medical device reimbursement. Medical device supply chain and international trade issues.
Issues related to medical technology regulation. Issues related to medical device reimbursement. Medical device supply chain and international trade issues.
TOLMAR, INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · RR
Advocacy around issues affecting the pharmaceutical industry, such as the Medicare Drug Price Negotiation Program under the Inflation Reduction Act.
ASANA VOICES via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · second_quarter · Q2
Advancing legislation on cardiovascular health and related issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVARTIS via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · second_quarter · Q2
Issues related to cell and gene therapy and radioligand therapies Pharmaceutical pricing Issues related to the development of therapies for rare diseases 340B Drug Discount Program Supply chain issues affecting pharmaceutical products Implementation of the Inflation reduction Act Pharmaceutical innovation PBM policy issues HR 1672 The Maintaining Investments in New Innovations (MINI) Act Intellectual property Issues Tariff issues affecting the pharmaceutical industry EPIC Act Most Favored Nation (MFN) policy
Filing targets: HOUSE OF REPRESENTATIVES, U.S. Trade Representative (USTR)
GRINDR LLC via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · second_quarter · Q2
HIV prevention, PEPFAR, family formation
Filing targets: HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), SENATE, State, Dept of (DOS)
ELI LILLY AND COMPANY via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · second_quarter · Q2
Issues related to the pharmaceutical industry Treat and Reduce Obesity Act Pharmaceutical tariffs Safe Drugs Act
Issues related to biotechnology legislation Diagnostic tests Clinical trial issues Issues related to supply chain
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELANCO ANIMAL HEALTH via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · second_quarter · Q2
Advocacy surrounding the development of pharmaceuticals for animals
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), SENATE, U.S. Trade Representative (USTR)
KYVERNA THERAPEUTICS, INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · second_quarter · Q2
Outreach regarding cell therapies for autoimmune diseases.
Filing targets: Food & Drug Administration (FDA), Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), White House Office
CAREQUEST INSTITUTE FOR ORAL HEALTH, INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · second_quarter · Q2
Oral health issues and screenings for oral cancer. Access to oral healthcare and issues related to Medicare Dental. P.L. 119-21 (H.R. 1): One Big Beautiful Bill implementation Fluoride Human Health Toxicity Assessment
Filing targets: Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
LONZA GROUP AG via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · second_quarter · Q2
Issues affecting healthcare manufacturing including supply chain, intellectual property, international trade, and tariffs.
Filing targets: Commerce, Dept of (DOC), SENATE, U.S. Trade Representative (USTR)
NOVAVAX, INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · second_quarter · Q2
Issues related to federal vaccine programs and vaccine regulatory frameworks. FDA funding and advocacy H.R.4121 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CARDINAL HEALTH, INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · second_quarter · Q2
General issues affecting the health care industry such as drug pricing, pharmaceutical drugs, medical devices, workforce shortages, and product shortages. Pharmaceutical tariffs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BAYLOR COLLEGE OF MEDICINE via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · second_quarter · Q2
NIH Federal grant issues FY27 Appropriations Proposed OMB Grant Rule Facilities and Administration issues Issues related to Dept. of Education negotiated rulemaking on P.L. 119-21 (H.R. 1) Commerce, Justice, Science (H.R. 5342; S. 2354) Labor-HHS (H.R. 5304; S. 2587)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELANCO ANIMAL HEALTH via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · second_quarter · RR
Advocacy surrounding the development of pharmaceuticals for animals and tariff exclusions for the same.
Advocacy surrounding the development of pharmaceuticals for animals and tariff exclusions for the same.
ASANA VOICES via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · second_quarter · RR
Advancing legislation on cardiovascular health and related issues.
NOVARTIS via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · first_quarter · Q1
Issues related to cell and gene therapy and radioligand therapies Pharmaceutical pricing Issues related to the development of therapies for rare diseases 340B Drug Discount Program Supply chain issues affecting pharmaceutical products Implementation of the Inflation reduction Act Pharmaceutical innovation PBM policy issues HR 1672 The Maintaining Investments in New Innovations (MINI) Act Intellectual property Issues Tariff issues affecting the pharmaceutical industry EPIC Act Most Favored Nation (MFN) policy
Filing targets: U.S. Trade Representative (USTR)
KYVERNA THERAPEUTICS, INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · first_quarter · Q1
Outreach regarding cell therapies for autoimmune diseases.
ELI LILLY AND COMPANY via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · first_quarter · Q1
Issues related to biotechnology legislation Diagnostic tests Clinical trial issues Issues related to supply chain
Filing targets: Commerce, Dept of (DOC), SENATE
LONZA GROUP AG via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · first_quarter · Q1
Issues affecting healthcare manufacturing including supply chain, intellectual property, international trade, and tariffs.
Filing targets: SENATE
CARDINAL HEALTH, INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · first_quarter · Q1
General issues affecting the health care industry such as drug pricing, pharmaceutical drugs, medical devices, workforce shortages, and product shortages. Pharmaceutical tariffs
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS)
BAYLOR COLLEGE OF MEDICINE via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · first_quarter · Q1
NIH Federal grant issues FY27 Appropriations Facilities and Administration issues Issues related to Dept. of Education negotiated rulemaking on P.L. 119-21 (H.R. 1) Commerce, Justice, Science (H.R. 5342; S. 2354) Labor-HHS (H.R. 5304; S. 2587)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVAVAX, INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · first_quarter · Q1
Issues related to federal vaccine programs and vaccine regulatory frameworks. FDA funding and advocacy H.R.4121 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PIERRE FABRE PHARMACEUTICALS INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · first_quarter · Q1
Issues related to drug development, rare disease innovations, and issues impacting the pharmaceutical industry.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS)
KYVERNA THERAPEUTICS, INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · first_quarter · RR
Outreach regarding cell therapies for autoimmune diseases.
NOVARTIS via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2025 · fourth_quarter · Q4
Issues related to cell and gene therapy and radioligand therapies Pharmaceutical pricing Issues related to the development of therapies for rare diseases 340B Drug Discount Program Supply chain issues affecting pharmaceutical products Implementation of the Inflation reduction Act Pharmaceutical innovation PBM policy issues HR 1672 The Maintaining Investments in New Innovations (MINI) Act Intellectual property Issues Tariff issues affecting the pharmaceutical industry EPIC Act Most Favored Nation (MFN) policy
Filing targets: HOUSE OF REPRESENTATIVES
LONZA GROUP AG via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2025 · fourth_quarter · Q4
Issues affecting healthcare manufacturing including supply chain, intellectual property, international trade, and tariffs.
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), SENATE, U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2025 · fourth_quarter · Q4
Issues related to biotechnology legislation Diagnostic tests Clinical trial issues Issues related to supply chain
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVAVAX, INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2025 · fourth_quarter · Q4
Issues related to federal vaccine programs and vaccine regulatory frameworks. FDA funding and advocacy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PIERRE FABRE PHARMACEUTICALS INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2025 · fourth_quarter · Q4
Issues related to drug development, rare disease innovations, and issues impacting the pharmaceutical industry.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BAYLOR COLLEGE OF MEDICINE via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2025 · fourth_quarter · Q4
NIH Federal grant issues H.R.1 One Big Beautiful Bill implementation FY26 Appropriations Facilities and Administration issues Issues related to Dept. of Education negotiated rulemaking on P.L. 119-21 (H.R. 1) Agriculture (H.R. 4121; S. 2256) Commerce, Justice, Science (H.R. 5342; S. 2354) Homeland Security (H.R. 4213) Labor-HHS (H.R. 5304; S. 2587) Military Construction and Veterans Affairs (H.R. 3944) State & Foreign Operations (H.R. 4779)
Filing targets: Education, Dept of, HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
CARDINAL HEALTH, INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2025 · fourth_quarter · Q4
General issues affecting the health care industry such as drug pricing, pharmaceutical drugs, medical devices, workforce shortages, and product shortages. The Preserving Patient Access to Long-Term Care Pharmacies Act (H.R. 5031 / S. 3159)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CARDINAL HEALTH, INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2025 · third_quarter · Q3
General issues affecting the health care industry such as drug pricing, pharmaceutical drugs, medical devices, workforce shortages, and product shortages.
Filing targets: HOUSE OF REPRESENTATIVES
PIERRE FABRE PHARMACEUTICALS INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2025 · third_quarter · Q3
Issues related to drug development, rare disease innovations, and issues impacting the pharmaceutical industry.
LONZA GROUP AG via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2025 · third_quarter · Q3
Issues affecting healthcare manufacturing including supply chain, intellectual property, international trade, and tariffs.
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), Natl Economic Council (NEC), SENATE, U.S. Trade Representative (USTR)
NOVAVAX, INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2025 · third_quarter · Q3
Issues related to federal vaccine programs and vaccine regulatory frameworks. FDA funding and advocacy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVARTIS via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2025 · third_quarter · Q3
Issues related to cell and gene therapy and radioligand therapies Pharmaceutical pricing Issues related to the development of therapies for rare diseases 340B Drug Discount Program Supply chain issues affecting pharmaceutical products Implementation of the Inflation reduction Act Pharmaceutical innovation PBM policy issues HR 1672 The Maintaining Investments in New Innovations (MINI) Act Intellectual property Issues Tariff issues affecting the pharmaceutical industry EPIC Act Most Favored Nation (MFN) policy
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE
PIERRE FABRE PHARMACEUTICALS INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2025 · third_quarter · RR
Issues related to drug development, rare disease innovations, and issues impacting the pharmaceutical industry.
LONZA GROUP AG via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2025 · third_quarter · RR
Issues affecting healthcare manufacturing including supply chain, intellectual property, international trade, and tariffs.
Issues affecting healthcare manufacturing including supply chain, intellectual property, international trade, and tariffs.
NOVAVAX, INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2025 · third_quarter · RR
Issues related to federal vaccine programs and vaccine regulatory frameworks. FDA funding and advocacy.
CARDINAL HEALTH, INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2025 · third_quarter · RR
General issues affecting the health care industry such as drug pricing, pharmaceutical drugs, medical devices, workforce shortages, and product shortages.